185 related articles for article (PubMed ID: 33554455)
1. Improving Strategies in the Development of Protein-Downregulation-Based Antiandrogens.
Zhang R; Huang C; Xiao X; Zhou J
ChemMedChem; 2021 Jul; 16(13):2021-2033. PubMed ID: 33554455
[TBL] [Abstract][Full Text] [Related]
2. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor modulators: a review of recent patents and reports (2012-2018).
Fujii S; Kagechika H
Expert Opin Ther Pat; 2019 Jun; 29(6):439-453. PubMed ID: 31092069
[TBL] [Abstract][Full Text] [Related]
4. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
5. Antiandrogens in prostate cancer endocrine therapy.
Culig Z; Bartsch G; Hobisch A
Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
[TBL] [Abstract][Full Text] [Related]
6. Development of 2-(5,6,7-Trifluoro-1
Leblanc E; Ban F; Cavga AD; Lawn S; Huang CF; Mohan S; Chang MEK; Flory MR; Ghaidi F; Lingadahalli S; Chen G; Yu IPL; Morin H; Lallous N; Gleave ME; Mohammed H; Young RN; Rennie PS; Lack NA; Cherkasov A
J Med Chem; 2021 Oct; 64(20):14968-14982. PubMed ID: 34661404
[TBL] [Abstract][Full Text] [Related]
7. "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.
Caboni L; Kinsella GK; Blanco F; Fayne D; Jagoe WN; Carr M; Williams DC; Meegan MJ; Lloyd DG
J Med Chem; 2012 Feb; 55(4):1635-44. PubMed ID: 22280402
[TBL] [Abstract][Full Text] [Related]
8. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
9. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives.
Ha S; Luo G; Xiang H
J Med Chem; 2022 Dec; 65(24):16128-16154. PubMed ID: 36459083
[TBL] [Abstract][Full Text] [Related]
11. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
Isaacsson Velho P; Carducci MA
Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
[TBL] [Abstract][Full Text] [Related]
12. Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.
Vasaitis TS; Njar VC
Future Med Chem; 2010 Apr; 2(4):667-80. PubMed ID: 21426013
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
14. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.
Kim GY; Song CW; Yang YS; Lee NR; Yoo HS; Son SH; Lee SJ; Park JS; Lee JK; Inn KS; Kim NJ
Molecules; 2021 Apr; 26(9):. PubMed ID: 33926033
[TBL] [Abstract][Full Text] [Related]
15. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
17. Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
Ferroni C; Varchi G
Curr Med Chem; 2019; 26(33):6053-6073. PubMed ID: 30209993
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
19. Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
Dalal K; Morin H; Ban F; Shepherd A; Fernandez M; Tam KJ; Li H; LeBlanc E; Lack N; Prinz H; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Sep; 157():1164-1173. PubMed ID: 30193215
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]